Abstract 4625
Background
With evolving gBRCAm BC guideline landscape, we present latest gBRCA testing rates among mBC US pts with HR+/HER2- or triple negative BC (TNBC); including clinical outcomes, treatment patterns and HRU in gBRCAm pts.
Methods
The Flatiron Health database was used in a real world retrospective analysis of mBC pts with HR+/HER2- or TNBC, ≥18 yrs old, diagnosed between Jan 2011-Feb 2018. Rates of gBRCA testing were assessed. One- to 5-yr overall survival (OS) post mBC diagnosis for gBRCAm HR+/HER2- and TNBC pts were estimated. Cox proportional hazards model was used to estimate OS of TNBC vs HR+/HER2-. Outcomes between TNBC vs HR+/HER2- pts were compared while adjusting for imbalances. Antineoplastic treatment was summarized and HRU patterns were analyzed using t-tests.
Results
The study included 12,021 mBC pts (10,291 HR+/HER2-; 1730 TNBC). Results for gBRCA testing were available for 16.7% of pts overall; (HR+/HER2-: 15.4%, TNBC: 24.2%). The most common 1st line treatments for gBRCAm TNBC were capecitabine (19%) and carboplatin/gemcitabine (15%) and 1st line treatments for gBRCAm HR+/HER2- included letrozole (10%) and fulvestrant (7%). Pts counts, OS estimates and HRU for gBRCAm carriers are shown in the table; Cox regression results showed lower OS for gBRCAm TNBC pts vs gBRCAm HR+/HER2- mBC pts, Hazard Ratio (HR+/HER2- / TNBC) and 95% CI 0.59 (0.34, 1.01). Estimated median OS and 5-yr OS rates are (33.9 mths, 22.3 mths) and (28.9%, 26.4%) for gBRCAm HR+/HER2- and TNBC pts respectively. Number of HRU visits per-pts-per-year were significantly higher among TNBC pts.
Conclusions
gBRCA testing rates among mBC pts with HR+/HER2- or TNBC were low. Among mBC pts with gBRCAm, 5-yr OS rates were < 29% for both HR+/HER2- and TNBC; poor prognosis and HRU burden demonstrates a significant unmet need for more targeted, less HRU-intensive treatment options among these pts.Table: 310P
| HR+/HER2- | TNBC | |
|---|---|---|
| Total Patients (N = 12,021) n (%) | 10,291 (85.6) | 1730 (14.4) |
| Patients with gBRCA test results (n = 2005) n (%) | 1587 (79.2) | 418 (20.8) |
| Patients with gBRCAm (n = 229) n (%) | 165 (72.1) | 64 (27.9) |
| gBRCAm patients with ≥ 1st Line antineoplastic treatment (n = 188) n (%) | 142 (75.5) | 46 (24.5) |
| Year | Overall Survival Estimates (%) | |
| 1 | 93.4 | 69.5 |
| 2 | 58.6 | 46.3 |
| 3 | 45.8 | 26.4 |
| 4 | 30.7 | 26.4 |
| 5 | 28.9 | 26.4 |
| Number of Health Resource Utilization Visits (per patient per year) mean (std dev) *p < 0.05 | ||
| Treatment Visits* | 17.4 (14.4) | 40.8 (21.8) |
| Lab Visits* | 24.2 (10.1) | 40.3 (44.2) |
| Vital Visits* | 27.4 (14.3) | 49.9 (66.8) |
| ALL* | 35.2 (30.3) | 65.0 (84.7) |
Clinical trial identification
Legal entity responsible for the study
Pfizer, Inc.
Funding
Pfizer, Inc.
Editorial Acknowledgement
Disclosure
R. Quek, J. Mardekian: Employee: Pfizer Inc.
Resources from the same session
4596 - Neoadjuvant Trial of nab-paclitaxel and Atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive Triple Negative Breast Cancer (TNBC)
Presenter: Jennifer Litton
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5349 - Prognostic implications of circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC)
Presenter: Carolyn Hall
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2568 - A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients
Presenter: Lothar Häberle
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5413 - Evaluation of the MammaTyper® as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes
Presenter: Peter A. Fasching
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2260 - Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy (NAST) in metaplastic breast cancer (MpBC)
Presenter: Clinton Yam
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4722 - Evaluation of Human epidermal growth factor receptor 2 overexpression (HER2+) after administration of neoadjuvant treatment (NAT) and prognostic impact in breast cancer (BC)
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4307 - Complete response (CR) to anthracycline-based chemotherapy using magnetic resonance imaging (MRI) predicts high rates of pathologic complete response (pCR) for triple negative breast cancer (TNBC) patients treated preoperatively with anthracycline and taxane-based regimens
Presenter: Maria Marin Alcala
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5018 - Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy (GBG89, Geparnuevo trial)
Presenter: Barbara Seliger
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3203 - Impact of breast cancer subtype on survival after lumpectomy versus mastectomy for early stage invasive breast cancer
Presenter: YU-CHEN Tsai
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4887 - Survival Outcomes of Dose Dense Neoadjuvant and Adjuvant Chemotherapy in Triple-Negative Breast Cancer Patients – Indian Scenario
Presenter: TANVI Sood
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract